Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 5/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10255074 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTESR2UCHL1SRC | |
| SCHEMBL1131364 | 0.91 | SRC (0.42) | ALDH1A1MAPTESR2UCHL1SRC | |
| SCHEMBL1068114 | 0.83 | HSD17B10 (0.43) | ALDH1A1SRCSMN1; SMN2 | |
| SCHEMBL1068111 | 0.83 | HSD17B10 (0.43) | ALDH1A1SRCSMN1; SMN2 | |
| SCHEMBL13898314 | 0.82 | MAPT (0.51) | ALDH1A1MAPTESR2UCHL1HSD11B1 | |
| SCHEMBL10254818 | 0.82 | NR1H2 (0.43) | UCHL1SRCHSD11B1MMP2NR1H2 | |
| SCHEMBL1130935 | 0.81 | CCNT1 (0.45) | NR1H2NR1H3PTPN1USP30HDAC1 | |
| SCHEMBL1130998 | 0.81 | CCNT1 (0.45) | NR1H2NR1H3PTPN1USP30HDAC1 | |
| SCHEMBL10260293 | 0.80 | UCHL1 (0.40) | UCHL1SRCMMP2NR1H2NR1H3 | |
| SCHEMBL7991005 | 0.79 | USP30 (0.45) | UCHL1SRCNR1H2NR1H3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155729-B1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-2178870-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | disclosed |
| EP-2155729-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-7501422-B2 | Prolinamide-tetrazole derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501422-B2 | Prolinamide-tetrazole derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| WO-2009025478-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | disclosed |
| US-20080306089-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20080306089-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-11 | — | — | US | disclosed |
| WO-2008148688-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306089-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, TAC3, NPSR1 | ALDH1A1 545/4885MAPT 467/4885ESR2 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.